Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

1141. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials

Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials McAlister F A, Stewart S, Ferrua S, McMurray J J CRD summary (...) This review investigated whether multidisciplinary out-patient interventions for patients with heart failure (HF) improve clinical outcomes. The results showed that a variety of multidisciplinary interventions reduce hospitalisation for HF, and that strategies which include follow-up by trained staff and/or access to HF clinics can reduce mortality and all-cause hospitalisations. Authors' objectives To update a previous meta-analysis on the effectiveness of multidisciplinary strategies for managing heart failure

DARE.2004

1142. Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity

Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity Exercise training for patients with heart failure: a systematic review of factors that improve mortality and morbidity Smart N, Marwick T H CRD summary This review looked at the effects of exercise training on people with heart failure. The authors found (...) that exercise programmes may reduce adverse events (temporary or permanent termination of the exercise programme, or death), but more evidence is needed to assess the effect on mortality alone. Given there were several methodological problems with the review, the evidence may be insufficient to support the conclusion. Authors' objectives To determine the effects of exercise training in people with heart failure. Searching MEDLINE (from 1966 to August 2003), Medscape (from 1979 to August 2003

DARE.2004

1143. Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure

Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure Galbreath A D, Krasuski R A, Smith B, Stajduhar K C, Kwan M D, Ellis R, Freeman G L Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A disease management (DM) programme for patients with congestive heart failure (CHF) was examined. The DM programme was administered by telephone. Calls were initially made weekly, with a transition to monthly

NHS Economic Evaluation Database.2004

1144. Economic effects of beta-blocker therapy in patients with heart failure

Economic effects of beta-blocker therapy in patients with heart failure Economic effects of beta-blocker therapy in patients with heart failure Economic effects of beta-blocker therapy in patients with heart failure Cowper P A, DeLong E R, Whellan D J, LaPointe N M, Califf R M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of beta-blockers (BB) for the treatment of patients with heart failure (HF). The BBs studied included carvedilol and metoprolol. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical cohort of patients with HF. Setting The setting was secondary care (outpatient). The economic study

NHS Economic Evaluation Database.2004

1145. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure

Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure Chen L, Hay J W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the use of implanted cardioverter defibrillators for preventing sudden death for congestive heart failure patients. This intervention was compared to conventional treatment, normally involving the use of beta-adrenoceptor blockers. Type of intervention Treatment

NHS Economic Evaluation Database.2004

1146. A matched-cohort study of health services utilization and financial outcomes for a heart failure disease-management program in elderly patients

A matched-cohort study of health services utilization and financial outcomes for a heart failure disease-management program in elderly patients A matched-cohort study of health services utilization and financial outcomes for a heart failure disease-management program in elderly patients A matched-cohort study of health services utilization and financial outcomes for a heart failure disease-management program in elderly patients Berg G D, Wadhwa S, Johnson A E Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a disease-management heart failure (HF) programme in elderly patients. This programme employed a structured, evidence-based, telephonic nursing intervention that was designed to provide patient education

NHS Economic Evaluation Database.2004

1147. Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan

Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Cost-effectiveness analysis of carvedilol for the treatment of chronic heart failure in Japan Inomata T, Izumi T, Kobayashi M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two treatments for the care of chronic heart failure (CHF) were under evaluation. The treatments compared were the addition of carvedilol to conventional therapies and conventional therapies alone. The conventional therapies included the concomitant use of angiotensin-converting enzyme (ACE) inhibitors, diuretics and digitalis. The treatment regimes were low-dose (5 mg/day

NHS Economic Evaluation Database.2004

1148. Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure

Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure Special report: cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure Samson D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Left-ventricular assist devices (LVADs) used as destination therapy for patients with end-stage heart failure (ESHF), and who were not transplant candidates, were examined. The device considered in the study was the Thoratec Heartmate VE (vented electric) Left Ventricular Assisted System. This comprised

NHS Economic Evaluation Database.2004

1149. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure

Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure Nichol G, Kaul P, Huszti E, Bridges J F P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) population comprised patients with reduced ventricular function and prolonged QRS. The base-case analysis considered patients with New York Heart Association (NYHA) Class III heart failure. Setting The setting was secondary care. The economic study was conducted by the University of Alberta Evidence-based Practice Centre, Canada. Dates to which data relate The effectiveness data were derived from a review of papers published between 2001 and 2004. The cost data were derived from 2003 manufacturers' price

NHS Economic Evaluation Database.2004

1150. Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial

Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial Transitional care of older adults hospitalized with heart failure: a randomized, controlled trial Naylor M D, Brooten D A, Campbell R L, Maislin G, McCauley K M, Schwartz J S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A 3-month programme of comprehensive transitional care (discharge planning and home follow-up) was examined in elders hospitalised for heart failure. Advanced practice nurses (APNs), who received a training programme guided by a multidisciplinary team of heart failure experts, delivered the programme

NHS Economic Evaluation Database.2004

1151. Is B-type natriuretic peptide-guided heart failure management cost-effective

Is B-type natriuretic peptide-guided heart failure management cost-effective Is B-type natriuretic peptide-guided heart failure management cost-effective Is B-type natriuretic peptide-guided heart failure management cost-effective Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of B-type natriuretic peptide (BNP)-guided heart failure management in patients with symptomatic chronic heart failure (CHF) was examined. BNP measurement was carried out every 3 months. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of symptomatic (New York Heart Association Class

NHS Economic Evaluation Database.2004

1152. A multicenter disease management program for hospitalized patients with heart failure

A multicenter disease management program for hospitalized patients with heart failure A multicenter disease management program for hospitalized patients with heart failure A multicenter disease management program for hospitalized patients with heart failure Tsuyuki R T, Fradette M, Johnson J A, Bungard T J, Eurich D T, Ashton T, Gordon W, Ikuta R, Kornder J, MacKay E, Manyari D, O'Reilly K, Semchuk W Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A two-stage programme for the management of patients hospitalised with heart failure (HF) was examined. In stage 1, a pharmacist or nurse assessed each patient and made recommendations to the physician to add or adjust angiotensin-converting enzyme (ACE) inhibitors and other HF

NHS Economic Evaluation Database.2004

1153. Elecsys (R) ProBNP immunoassay for the diagnosis of congestive heart failure

Elecsys (R) ProBNP immunoassay for the diagnosis of congestive heart failure Elecsys (R) ProBNP immunoassay for the diagnosis of congestive heart failure Elecsys (R) ProBNP immunoassay for the diagnosis of congestive heart failure Bywood P, Merlin T, Braunack-Mayer A, Hiller J E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bywood P (...) , Merlin T, Braunack-Mayer A, Hiller J E. Elecsys (R) ProBNP immunoassay for the diagnosis of congestive heart failure. Adelaide: Adelaide Health Technology Assessment (AHTA). 2004 Authors' conclusions Congestive heart failure (CHF), which occurs when the heart fails to fill normally or to expel blood effectively, is characterised by breathlessness and oedema. CHF is a major health problem in Australia, accounting for more than 2,500 deaths and over 40,000 hospitalisations per year. Echocardiography

Health Technology Assessment (HTA) Database.2004

1154. Levosimendan for acute heart failure - horizon scanning review

Levosimendan for acute heart failure - horizon scanning review Levosimendan for acute heart failure - horizon scanning review Levosimendan for acute heart failure - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Levosimendan for acute heart failure - horizon scanning review. Birmingham: National Horizon (...) Scanning Centre (NHSC). 2004 Authors' objectives This study aims to summarise the currently available evidence on levosimendan for acute heart failure. Authors' conclusions Levosimendan (Simdax) is a short-term add on treatment for acutely decompensated heart failure that is in phase III clinical trials. Clinical trials published to date have found that patients given levosimendan experienced a positive haemodynamic benefit, and a lower risk of death and worsening heart failure than patients receiving

Health Technology Assessment (HTA) Database.2004

1155. Cardiac resynchronization therapy for congestive heart failure

Cardiac resynchronization therapy for congestive heart failure Cardiac resynchronization therapy for congestive heart failure Cardiac resynchronization therapy for congestive heart failure McAlister F, Ezekowitz J, Wiebe N, Rowe B, Spooner C, Crumley E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McAlister F, Ezekowitz J, Wiebe N, Rowe (...) B, Spooner C, Crumley E. Cardiac resynchronization therapy for congestive heart failure. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 106. 2004 Authors' objectives The objectives of this review were to determine the efficacy, safety, and cost-effectiveness of cardiac resynchronization therapy (CRT) in adults with symptomatic congestive heart failure (CHF). Authors' conclusions In patients with NYHA Class III or IV CHF despite medical

Health Technology Assessment (HTA) Database.2004

1156. Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure

Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure Samson D Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation Samson D. Cost-effectiveness of left-ventricular assist devices as destination therapy for end-stage heart failure. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 19(02). 2004 Authors' objectives This cost-effectiveness analysis addresses the use of left-ventricular assist

Health Technology Assessment (HTA) Database.2004

1157. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. 15152059 2004 05 20 2004 05 25 2013 11 21 1533-4406 350 21 2004 May 20 The New England journal of medicine N. Engl. J. Med. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. 2140-50 We tested the hypothesis that prophylactic cardiac-resynchronization therapy in the form of biventricular stimulation with a pacemaker with (...) or without a defibrillator would reduce the risk of death and hospitalization among patients with advanced chronic heart failure and intraventricular conduction delays. A total of 1520 patients who had advanced heart failure (New York Heart Association class III or IV) due to ischemic or nonischemic cardiomyopathies and a QRS interval of at least 120 msec were randomly assigned in a 1:2:2 ratio to receive optimal pharmacologic therapy (diuretics, angiotensin-converting-enzyme inhibitors, beta

NEJM2004

1158. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. 15533851 2004 11 11 2004 11 22 2013 11 21 1533-4406 351 20 2004 Nov 11 The New England journal of medicine N. Engl. J. Med. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. 2049-57 We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response (...) to this therapy. A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. The study was terminated early owing

NEJM2004

1159. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 15113814 2004 04 28 2004 04 30 2016 10 17 1538-3598 291 16 2004 Apr 28 JAMA JAMA Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 1963-71 Nearly 1 million hospitalizations for chronic heart failure occur yearly in the United States, with most related to worsening systemic (...) congestion. Diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function. To evaluate the short- and intermediate-term effects of tolvaptan in patients hospitalized with heart failure. Randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, phase 2 trial

JAMA2004

1160. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure.

Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. BACKGROUND: Loop diuretics, when given as intermittent bolus injections in acutely decompensated heart failure, may cause fluctuations in intravascular volume, increased toxicity and development of tolerance. Continuous infusion has been proposed to avoid these complications and result in greater diuresis, hopefully leading to faster symptom resolution, decrease in morbidity and possibly, mortality (...) . OBJECTIVES: To compare the effects and adverse effects of continuous intravenous infusion of loop diuretics with those of bolus intravenous administration among patients with congestive heart failure Class III-IV. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 2, 2003), MEDLINE (1966 to 2003), EMBASE (1980 to 2003) and the HERDIN database. We also contacted pharmaceutical companies. SELECTION CRITERIA: Randomized controlled trials comparing

Cochrane2004